What is omaveloxolone (Skyclarys)?
Omaveloxolone is the active ingredient in Skyclarys, an oral medicine used to treat Friedreich’s ataxia (FA), a rare, inherited neurodegenerative disease. [1]
What does Skyclarys treat?
Skyclarys is indicated for treating Friedreich’s ataxia in people who are eligible based on the product’s approved label for the relevant country/region. [1]
How is Skyclarys taken?
Skyclarys is taken by mouth (oral dosing). The exact dose schedule depends on the prescribing information and patient factors, including liver-related considerations and use with other medicines. [1]
What side effects do people ask about?
Common side effects reported for omaveloxolone/Skyclarys include gastrointestinal symptoms (such as nausea) and other treatment-related effects listed in the prescribing information. [1]
Who makes Skyclarys, and where is it available?
Skyclarys is marketed as a branded product for omaveloxolone. Availability and eligibility depend on local regulatory approval and pharmacy coverage. [1]
What precautions matter (for example, liver health or drug interactions)?
Because omaveloxolone is metabolized and can affect clinical labs, clinicians typically check relevant patient history and monitoring needs described in the prescribing information, including considerations for hepatic function and potential drug interactions. [1]
Is Skyclarys a cure?
Skyclarys is a disease treatment intended to manage Friedreich’s ataxia rather than cure the underlying genetic condition. [1]
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/skyclarys